Could fewer chemo cycles be just as good for some lymphoma patients?

NCT ID NCT05018520

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This study compares two treatment schedules for people with a common type of lymphoma (DLBCL) that is low-risk and not large. All participants first receive 4 cycles of standard chemo (R-CHOP). Those who respond well are then randomly assigned to get either 4 more doses of rituximab alone or 2 more cycles of R-CHOP plus 2 rituximab doses. The goal is to see if the shorter chemo approach works as well with fewer side effects. About 640 adults aged 14–75 are being recruited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B CELL LYMPHOMA